Senju Pharmaceutical Co. Ltd., of Osaka, Japan, will pay Alameda, Calif.-based Insite Vision Inc. an undisclosed amount for the right to develop and market ocular antibiotics incorporating Insite's Durasite drug delivery platfom in Japan. The deal includes an up-front license fee, additional development milestones fees and a percentage royalty on net sales.